系统性红斑狼疮患者疾病进展:SPOCS前瞻性观察队列分析
SPOCS队列纳入826例接受标准治疗的中重度活动性SLE成人患者,每半年随访至36个月,按基线IFN基因特征分组比较。结果显示疾病活动度稳定或下降,但DORIS缓解与LLDAS达标率低、器官损害增加;第36个月时基线IFNGS分组间无明确差异。
要点
- 基线IFNGS高者较IFNGS低者更年轻且使用糖皮质激素比例更高。
- SLEDAI-2K从基线至第36个月下降(9.8±4.6至5.7±7.7),与基线IFNGS无关。
- 任何时间点DORIS缓解达标<15%、LLDAS达标<20%,第36个月IFNGS分组间无明确差异。
核心结论
- SPOCS队列中疾病活动度随时间稳定或降低,但治疗目标达标率低且器官损害增加。
- 第36个月时按基线IFNGS分组未见明确差异。
研究设计与样本
- SLE前瞻性观察队列研究(SPOCS;NCT03189875),纳入826例接受标准治疗的中重度活动性SLE成人患者。
- 基线后每半年评估一次,随访≤36个月。
主要发现
- 入组时距SLE诊断平均11.1±9.2年,70.8%(531/750)为IFNGS-high。
- 基线时IFNGS-high vs IFNGS-low患者更年轻(42.9±13.6 vs 50.8±12.9岁),使用糖皮质激素比例更高[68.7%(365/531) vs 56.2%(123/219)]。
- SLEDAI-2K在基线、第6个月和第24个月IFNGS-high患者中更高;SLEDAI-2K从基线至第36个月下降(9.8±4.6至5.7±7.7),与基线IFNGS无关。
- SDI在基线、第12个月和第24个月IFNGS-high患者中更低,但随时间增加,与基线IFNGS无关。
- 至第36个月44.7%(183/409)经历至少一次 flares;年化 flare 率在第30和第36个月IFNGS-high较IFNGS-low患者更高。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We describe disease progression in patients from the SLE Prospective Observational Cohort Study (SPOCS; NCT03189875), investigating differences by baseline IFN gene signature (IFNGS) status. METHODS: Adults with moderate to severe SLE activity receiving standard of care were assessed biannually for ≤36 months post-baseline (study entry). SLEDAI-2000 (SLEDAI-2K), Physician Global Assessment, Safety of Estrogen in Lupus Erythematosus National Assessment (SELENA)-SLEDAI flare number and severity, SLICC/ACR Damage Index (SDI) and remission [Definition of Remission in SLE (DORIS)]/Lupus Low Disease Activity State (LLDAS) attainment were evaluated. RESULTS: At enrolment (n = 826), mean ± s.d. time since SLE diagnosis was 11.1 ± 9.2 years; 70.8% (531/750) of patients were IFNGS-high. At baseline, IFNGS-high vs IFNGS-low patients were younger (42.9 ± 13.6 vs 50.8 ± 12.9 years) and more were using glucocorticoids [68.7% (365/531) vs 56.2% (123/219)]. SLEDAI-2K was higher at baseline, month 6 and month 24 in IFNGS-high patients; SLEDAI-2K decreased from baseline to month 36 (9.8 ± 4.6-5.7 ± 7.7) regardless of baseline IFNGS. SDI was lower at baseline, month 12 and month 24 in IFNGS-high patients, but increased over time regardless of baseline IFNGS. By month 36, 44.7% (183/409) experienced one or more flares; annualized flare rates were higher in IFNGS-high vs IFNGS-low patients at months 30 and 36. DORIS remission or LLDAS was attained by <15% and <20% of patients at any timepoint, with no differences between IFNGS groups except lower remission attainment in IFNGS-high patients at month 6. CONCLUSION: In the SPOCS cohort, disease activity was stable or reduced over time, but treatment target attainment was low and organ damage increased. At month 36, there were no clear differences by baseline IFNGS. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; NCT03189875.
引用
- Morand EF, Furie R, Aringer M, et al. Disease progression in patients with systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS). Rheumatology (Oxford). 2026. PMID: 41217773. doi:10.1093/rheumatology/keaf599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。